{"content":"<li class=\"n-box-item date-title\" data-end=\"1387342799\" data-start=\"1387256400\" data-txt=\"Friday, December 20, 2019\">Tuesday, December 17, 2013</li><li class=\"n-box-item sa-box-item\" data-id=\"1470291\" data-ts=\"1387320738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCAR\" target=\"_blank\">DCAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1470291-wpcs-plus-52_1-percent-ah-acquires-btx-trader-in-equity-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WPCS +52.1% AH, acquires BTX Trader in equity deal</a></h4><ul><li>WPCS International (WPCS) shares <font color=\"green\">rocket 52.1%</font> AH after the company acquires BTX Trader, an early stage tech firm developing a proprietary <a href=\"http://www.btxtrader.com/\" target=\"_blank\">bitcoin trading platform</a>, for 2,348 Series E preferred shares (stated value of $1,000, convertible at $3.50/share, 12% IR) and warrants to purchase 1.5M shares of common stock at a price of $5/share.</li></ul><div class=\"tiny-share-widget\" data-id=\"1470291\" data-linked=\"WPCS +52.1% AH, acquires BTX Trader in equity deal\" data-tweet=\"$DCAR - WPCS +52.1% AH, acquires BTX Trader in equity deal https://seekingalpha.com/news/1470291-wpcs-plus-52_1-percent-ah-acquires-btx-trader-in-equity-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/1470291-wpcs-plus-52_1-percent-ah-acquires-btx-trader-in-equity-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1470141\" data-ts=\"1387316709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REGI\" target=\"_blank\">REGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1470141-renewable-energy-to-acquire-syntroleum-in-stock-deal-plus-4-percent-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renewable Energy to acquire Syntroleum in stock deal, +4% AH</a></h4><ul>\n<li>Renewable Energy (NASDAQ:<a href=\"https://seekingalpha.com/symbol/REGI\" title=\"Renewable Energy Group, Inc\">REGI</a>) agrees to acquire Syntroleum (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SYNM\" title=\"Syntroleum Corporation\">SYNM</a>) for 3.796M shares of REGI, which would result in SYNM  shareholders receiving 0.3809 shares  of REGI common stock for each outstanding  share of SYNM common  stock.</li>\n<li>SYNM and its 50%-owned subsidiary Dynamic Fuels offer an       attractive entry path for REGI into renewable diesel, REGI CEO Daniel Oh says.</li>\n<li>SYNM <font color=\"green\">+50%</font>, REGI <font color=\"green\">+4%</font> AH.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1470141\" data-linked=\"Renewable Energy to acquire Syntroleum in stock deal, +4% AH\" data-tweet=\"$REGI $REGI $SYNM - Renewable Energy to acquire Syntroleum in stock deal, +4% AH https://seekingalpha.com/news/1470141-renewable-energy-to-acquire-syntroleum-in-stock-deal-plus-4-percent-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/1470141-renewable-energy-to-acquire-syntroleum-in-stock-deal-plus-4-percent-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469951\" data-ts=\"1387314546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469951-jabil-circuit-misses-by-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jabil Circuit misses by $0.03, beats on revenue</a></h4><ul>     <li>Jabil Circuit (NYSE:<a href=\"https://seekingalpha.com/symbol/JBL\" title=\"Jabil Inc.\">JBL</a>): FQ1 EPS of $0.51 <font color=\"red\">misses by $0.03</font>.</li>\n<li>Revenue of $4.6B <font color=\"green\">beats by $0.11B</font>. Shares  <font color=\"red\">-5.2%</font> AH. (PR)</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469951\" data-linked=\"Jabil Circuit misses by $0.03, beats on revenue\" data-tweet=\"$JBL - Jabil Circuit misses by $0.03, beats on revenue https://seekingalpha.com/news/1469951-jabil-circuit-misses-by-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1469951-jabil-circuit-misses-by-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469911\" data-ts=\"1387314300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAY\" target=\"_blank\">PAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469911-verifone-beats-by-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VeriFone beats by $0.01, beats on revenue</a></h4><ul>     <li>VeriFone (NYSE:<a href=\"https://seekingalpha.com/symbol/PAY\" title=\"VeriFone Systems, Inc.\">PAY</a>): FQ4 EPS of $0.27 <font color=\"green\">beats by $0.01</font>.</li>\n<li>Revenue of $432.0M <font color=\"green\">beats by $10.5M</font>. Shares <font color=\"green\">2.4%</font>  AH. (PR)</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469911\" data-linked=\"VeriFone beats by $0.01, beats on revenue\" data-tweet=\"$PAY - VeriFone beats by $0.01, beats on revenue https://seekingalpha.com/news/1469911-verifone-beats-by-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/1469911-verifone-beats-by-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469811\" data-ts=\"1387313224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMB\" target=\"_blank\">WMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469811-williams-cos-plus-4_1-percent-as-corvex-soroban-take-activist-role\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Williams Cos. +4.1% as Corvex, Soroban take activist role</a></h4><ul>     <li>Williams Cos. (<a href='https://seekingalpha.com/symbol/WMB' title='Williams Companies Inc'>WMB</a> <font color='green'>+4.1%</font>) is among the day's best performers in the S&amp;P 500 after Corvex Management and Soroban Capital revealed they <a href=\"https://seekingalpha.com/currents/post/1467751\" target=\"_blank\">own a combined 5.3% of WMB shares</a> and have been in discussions with the company, including asking for board seats and opportunities for deals in the midstream segment.</li>     <li>Corvex, run by Keith Meister, typically <a href=\"http://blogs.wsj.com/moneybeat/2013/12/17/williams-cos-shares-jump-as-corvex-soroban-turn-activist\" target=\"_blank\">works behind the scenes</a> though it has engaged in some public fights, including an ongoing rumble with Commonwealth REIT; Soroban, run by Eric Mandelblatt, is heavily invested in energy stocks but it hasn&rsquo;t filed a 13D in the few years it has been operating.</li></ul><div class=\"tiny-share-widget\" data-id=\"1469811\" data-linked=\"Williams Cos. +4.1% as Corvex, Soroban take activist role\" data-tweet=\"$WMB - Williams Cos. +4.1% as Corvex, Soroban take activist role https://seekingalpha.com/news/1469811-williams-cos-plus-4_1-percent-as-corvex-soroban-take-activist-role?source=tweet\" data-url=\"https://seekingalpha.com/news/1469811-williams-cos-plus-4_1-percent-as-corvex-soroban-take-activist-role\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469771\" data-ts=\"1387311852\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWEN\" target=\"_blank\">BWEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469771-broadwind-energy-plus-14-percent-on-buffett-deal-which-signals-wind-power-legitimacy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadwind Energy +14% on Buffett deal which signals wind power legitimacy</a></h4><ul>     <li>Broadwind Energy (<a href=\"https://seekingalpha.com/symbol/BWEN\" title=\"Broadwind Energy, Inc.\">BWEN</a> <font color=\"green\">+14.4%</font>) is set to be a major beneficiary of Siemens <a href=\"https://seekingalpha.com/currents/post/1466151\" target=\"_blank\">$1B-plus power contract</a> with MidAmerican Energy, supplying the towers for the 448 wind turbines that will equip five wind power projects in Iowa.</li>     <li>The move by Warren Buffett\u2019s utility company shows how a drop in equipment costs is making  renewable energy <a href=\"http://www.bloomberg.com/news/2013-12-17/wind-power-rivals-coal-with-1-billion-order-from-buffett.html\" target=\"_blank\">more competitive with power from fossil fuels</a> - a boost for suppliers including BWEN, Siemens (<a href=\"https://seekingalpha.com/symbol/SI\" title=\"Silvergate Capital\">SI</a>), <a href=\"https://seekingalpha.com/symbol/GE\" title=\"General Electric\">GE</a> and Vestas (<a href=\"https://seekingalpha.com/symbol/VWDRY\" title=\"Vestas Wind Systems A/S ADR\">OTCPK:VWDRY</a>, <a href=\"https://seekingalpha.com/symbol/VWSYF\" title=\"Vestas Wind Systems A/S\">OTCPK:VWSYF</a>), and a threat to coal miners (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/KOL\" title=\"VanEck Vectors Coal ETF\">KOL</a>).</li>\n<li>MidAmerican expects to close some coal-powered plants in 2015 as the price of wind power (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/FAN\" title=\"First Trust Global Wind Energy ETF\">FAN</a>) continues to slide, an exec says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469771\" data-linked=\"Broadwind Energy +14% on Buffett deal which signals wind power legitimacy\" data-tweet=\"$BWEN $BWEN $SIEGY - Broadwind Energy +14% on Buffett deal which signals wind power legitimacy https://seekingalpha.com/news/1469771-broadwind-energy-plus-14-percent-on-buffett-deal-which-signals-wind-power-legitimacy?source=tweet\" data-url=\"https://seekingalpha.com/news/1469771-broadwind-energy-plus-14-percent-on-buffett-deal-which-signals-wind-power-legitimacy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469761\" data-ts=\"1387311822\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AER\" target=\"_blank\">AER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469761-aercap-continues-to-fly-following-deal-for-ilfc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AerCap continues to fly following deal for ILFC</a></h4><ul>\n<li>AerCap's (<a href=\"https://seekingalpha.com/symbol/AER\" title=\"AerCap Holdings N.V.\">AER</a> <font color=\"green\">+6.4%</font>) gains today put the stock more than 40% higher since the deal with <a href=\"https://seekingalpha.com/symbol/AIG\" title=\"American International Group Inc\">AIG</a> was announced yesterday, and Deutsche's Michael Linenberg says there's more to come, <a href=\"http://www.streetinsider.com/Analyst+Comments/AerCap+%28AER%29+Flys+Higher+after+ILFC+Deal%3B+Deutsche+Bank+Raises+Target+to+%2440/8986917.html\" target=\"_blank\">reiterating his Buy rating </a>and boosting the price target to $40 from $27.</li>\n<li>\"We expect the deal to be accretive for AER shareholders on the onset, in light of the $600M of expected annual synergies and the attractive price at which the portfolio will be acquired,\"says Linenberg. \"Moreover, AerCap is inheriting ILFC\u2019s order book of 385 in-demand aircraft, which should lead to a strong/relatively predictable stream of CF/EPS for the foreseeable future.\"</li>\n<li>For AIG, the deal - at the moment - is less sale than a swap, as the insurer will be an owner of 46% of AER's common stock and will still include ILFC's operating results on its own books.</li>\n<li>Writing in <em>Barron's</em>, Dimitra Defotis, <a href=\"http://online.barrons.com/article/SB50001424053111904399004579262153820989552.html?mod=googlenews_barrons\" target=\"_blank\">says the spotlight now turns</a> to AIG's core financial operations, and that may not be a good thing based on last quarter's results. Yes, AIG trades at a discount to book, but with analysts not projecting earnings growth next year, that discount could be warranted.</li>\n<li>Maybe the most bullish case for AIG at the moment is the moonshot in AerCap may allow the insurer to unload its stake at a sweet price (the lockup agreements aren't yet known).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469761\" data-linked=\"AerCap continues to fly following deal for ILFC\" data-tweet=\"$AER $AER $AIG - AerCap continues to fly following deal for ILFC https://seekingalpha.com/news/1469761-aercap-continues-to-fly-following-deal-for-ilfc?source=tweet\" data-url=\"https://seekingalpha.com/news/1469761-aercap-continues-to-fly-following-deal-for-ilfc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469751\" data-ts=\"1387311738\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAVB\" target=\"_blank\">NAVB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469751-navidea-biopharma-submits-snda-for-lymphoseek\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navidea Biopharma submits sNDA for Lymphoseek</a></h4><ul>\n<li>Shares of        Navidea Biopharmaceuticals (<a href=\"https://seekingalpha.com/symbol/NAVB\" title=\"Navidea Biopharmaceuticals\">NAVB</a> <font color=\"green\">+5.4%</font>) are trading higher on the session.<br>\n</li>\n<li>The company says it has submitted an sNDA for <a href=\"https://seekingalpha.com/currents/search?query=Lymphoseek\" target=\"_blank\">Lymphoseek</a> in patients with head and neck cancer (Fast Track designation <a href=\"https://seekingalpha.com/currents/post/1455581\" target=\"_blank\">granted</a> last week).</li>\n<li>The company calls the submission an \"important step toward       NAVB's goal of helping this patient population who generally face       extensive surgery to properly stage their cancer.\"</li>\n<li>CEO Mark Pykett also notes that \"if this sNDA is approved,       Lymphoseek will be the only approved agent for SLN detection in this       patient population.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469751\" data-linked=\"Navidea Biopharma submits sNDA for Lymphoseek\" data-tweet=\"$NAVB - Navidea Biopharma submits sNDA for Lymphoseek https://seekingalpha.com/news/1469751-navidea-biopharma-submits-snda-for-lymphoseek?source=tweet\" data-url=\"https://seekingalpha.com/news/1469751-navidea-biopharma-submits-snda-for-lymphoseek\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469711\" data-ts=\"1387310579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469711-morgan-stanley-talks-abbvie-targacept\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley talks AbbVie, Targacept</a></h4><ul>\n<li>Morgan Stanley is out <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/12/4161338/update-morgan-stanley-reiterates-on-abbvie-after-competi\" target=\"_blank\">reiterating</a> an Overweight rating on AbbVie (<a href=\"https://seekingalpha.com/symbol/ABBV\" title=\"AbbVie Inc.\">ABBV</a> <font color=\"green\">+0.6%</font>) in the wake of Targacept's (TRGT <font color=\"red\">-31.6%</font>) TC-5619 schizophrenia <a href=\"https://seekingalpha.com/currents/post/1467491\" target=\"_blank\">miss</a>.</li>\n<li>\"This drug is similar to ABBV's ABT-126, which is being tested in Phase 2b  in both cognition in Alzheimer's and CDS,\" analyst David Risinger notes, adding that his firm has been \"estimating 20%  odds of ABBV success in one of the two indications.\u201d</li>\n<li>$57 price target removed.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469711\" data-linked=\"Morgan Stanley talks AbbVie, Targacept\" data-tweet=\"$ABBV $ABBV $CBIO - Morgan Stanley talks AbbVie, Targacept https://seekingalpha.com/news/1469711-morgan-stanley-talks-abbvie-targacept?source=tweet\" data-url=\"https://seekingalpha.com/news/1469711-morgan-stanley-talks-abbvie-targacept\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469691\" data-ts=\"1387310270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGO\" target=\"_blank\">AVGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469691-avago-chip-stocks-rally-as-lsi-deal-gets-praised-fuels-m-and-a-hopes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avago, chip stocks rally as LSI deal gets praised, fuels M&amp;A hopes</a></h4><ul>\n<li>Avago (<a href=\"https://seekingalpha.com/symbol/AVGO\" title=\"Broadcom Limited\">AVGO</a> <font color=\"green\">+7.6%</font>) is now <font color=\"green\">up 18%</font> (good for a $2.1B increase in market cap) since announcing a <a href=\"https://seekingalpha.com/currents/post/1465901\" target=\"_blank\">$6.6B deal</a> to acquire LSI yesterday morning. Many of its chip industry peers have also rallied; the Philadelphia Semiconductor Index (<a href=\"https://seekingalpha.com/symbol/SOXX\" title=\"iShares PHLX SOX Semiconductor Sector Index ETF\">SOXX</a> <font color=\"green\">+1.2%</font>) is <font color=\"green\">up 2.5%</font> over the last two days.</li>\n<li>The sharply contrasting nature of Avago and LSI's product lines - Avago depends heavily on RF and optical component sales, while LSI depends on storage controllers/adapters and network processors - could be fueling hopes other chipmakers will use M&amp;A to expand their product lines and achieve greater scale.</li>\n<li>Today's notable gainers include EZchip (EZCH <font color=\"green\">+6.7%</font>), OmniVision (<a href=\"https://seekingalpha.com/symbol/OVTI\" title=\"OmniVision Technologies, Inc.\">OVTI</a> <font color=\"green\">+3.6%</font>), Skyworks (<a href=\"https://seekingalpha.com/symbol/SWKS\" title=\"Skyworks Solutions, Inc.\">SWKS</a> <font color=\"green\">+3%</font>), Cavium (CAVM <font color=\"green\">+3%</font>), Audience (<a href=\"https://seekingalpha.com/symbol/ADNC\" title=\"Audience, Inc\">ADNC</a> <font color=\"green\">+5.8%</font>), Cirrus Logic (<a href=\"https://seekingalpha.com/symbol/CRUS\" title=\"Cirrus Logic, Inc.\">CRUS</a> <font color=\"green\">+3.4%</font>), and Semtech (<a href=\"https://seekingalpha.com/symbol/SMTC\" title=\"Semtech Corporation\">SMTC</a> <font color=\"green\">+3%</font>). Cirrus and OmniVision, which both depend heavily on Apple orders, might also be getting a boost from a positive <a href=\"https://twitter.com/thenotablecalls/status/412989940679446528\" target=\"_blank\">Q4 pre-announcement</a> from Germany's Dialog Semi (gets ~70% of its sales from Apple).</li>\n<li>Several firms have hiked their Avago PTs in response to the LSI deal, which is set to be financed with $4.6B in debt and a $1B convertible note investment from Silver Lake (conversion price of just $48.04). <a href=\"http://www.streetinsider.com/Analyst+Comments/Avago+%28AVGO%29+Target+Lifted+to+%2460+at+Nomura+on+LSI+Deal/8984655.html\" target=\"_blank\">Nomura</a> expects the deal to lift Avago's 2015 EPS by $1.00-$1.50; Avago is promising $200M/year in synergies by the end of FY15 (ends Nov. '15). RBC thinks FY15 EPS of ~$5 is possible; the consensus is at $3.89.</li>\n<li>Chip ETFs: <a href=\"https://seekingalpha.com/symbol/SMH\" title=\"VanEck Vectors Semiconductor ETF\">SMH</a>, <a href=\"https://seekingalpha.com/symbol/XSD\" title=\"SPDR S&amp;P Semiconductor ETF\">XSD</a>, <a href=\"https://seekingalpha.com/symbol/PSI\" title=\"Invesco Dynamic Semiconductors Portfolio ETF\">PSI</a>, <a href=\"https://seekingalpha.com/symbol/SOXL\" title=\"Direxion Daily Semiconductor 3x Bull Shares ETF\">SOXL</a>, <a href=\"https://seekingalpha.com/symbol/USD\" title=\"ProShares Ultra Semiconductors ETF\">USD</a>, <a href=\"https://seekingalpha.com/symbol/SOXS\" title=\"Direxion Daily Semiconductor 3x Bear Shares ETF\">SOXS</a>, <a href=\"https://seekingalpha.com/symbol/SSG\" title=\"ProShares UltraShort Semiconductors ETF\">SSG</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469691\" data-linked=\"Avago, chip stocks rally as LSI deal gets praised, fuels M&amp;A hopes\" data-tweet=\"$AVGO $AVGO $SOXX - Avago, chip stocks rally as LSI deal gets praised, fuels M&amp;A hopes https://seekingalpha.com/news/1469691-avago-chip-stocks-rally-as-lsi-deal-gets-praised-fuels-m-and-a-hopes?source=tweet\" data-url=\"https://seekingalpha.com/news/1469691-avago-chip-stocks-rally-as-lsi-deal-gets-praised-fuels-m-and-a-hopes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469581\" data-ts=\"1387307849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VICL\" target=\"_blank\">VICL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469581-vical-initiates-study-of-hsvminus-2-vaccine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vical initiates study of HSV-2 vaccine</a></h4><ul>\n<li>Vical (<a href=\"https://seekingalpha.com/symbol/VICL\" title=\"Vical Incorporated\">VICL</a> <font color=\"green\">+2.5%</font>) initiates a Phase 1/2 study of a Vaxfectin (an adjuvant) -formulated HSV-2 vaccine.</li>\n<li>The company hopes the vaccine can reduce viral shedding by \"harnessing the immune system [thus] freeing subjects from daily, lifelong antiviral drug usage.\" (PR)</li>\n<li>As for market potential, SA contributor Theodore Cohen says \"current estimates suggest that a therapeutic HSV-2 vaccine <a href=\"https://seekingalpha.com/article/1903301-vical-initiates-trial-of-therapeutic-hsv-2-vaccine\" target=\"_blank\">could  generate</a> as much as a billion dollars in annual sales at its peak.\"</li>\n<li>For more on VICL's work on HSV-2, see Cohen's September piece <a href=\"https://seekingalpha.com/article/1688532-vicals-herpes-vaccine-an-update\" target=\"_blank\">here</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469581\" data-linked=\"Vical initiates study of HSV-2 vaccine\" data-tweet=\"$VICL $BBI - Vical initiates study of HSV-2 vaccine https://seekingalpha.com/news/1469581-vical-initiates-study-of-hsvminus-2-vaccine?source=tweet\" data-url=\"https://seekingalpha.com/news/1469581-vical-initiates-study-of-hsvminus-2-vaccine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469571\" data-ts=\"1387307686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBA\" target=\"_blank\">PBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469571-pembina-plus-4_3-percent-on-pipeline-expansion-news-analyst-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pembina +4.3% on pipeline expansion news, analyst upgrade</a></h4><ul>     <li>Pembina Pipeline (<a href=\"https://seekingalpha.com/symbol/PBA\" title=\"Pembina Pipeline Corp.\">PBA</a> <font color=\"green\">+4.3%</font>) is <a href=\"http://www.streetinsider.com/Upgrades/TD+Securities+Raises+Pembina+Pipeline+Corp.+%28PBA%29+to+Buy+following+Phase+III+Pipeline+Expansion/8984924.html\" target=\"_blank\">upgraded to Buy</a> from Hold with a $38 price target, up from $36, at TD Securities, which believes PBA's <a href=\"https://seekingalpha.com/currents/post/1466751\" target=\"_blank\">phase-3 pipeline system expansion</a> further enhances its highly integrated and substantial legacy asset footprint.</li>     <li>PBA said it secured sufficient contracts for a $2B expansion, slightly  larger than TD had expected and underpins the expansion positively; the project underscores PBA's competitive positioning and its ability to secure incremental business to support growing volumes coming from western Canada, the firm says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469571\" data-linked=\"Pembina +4.3% on pipeline expansion news, analyst upgrade\" data-tweet=\"$PBA - Pembina +4.3% on pipeline expansion news, analyst upgrade https://seekingalpha.com/news/1469571-pembina-plus-4_3-percent-on-pipeline-expansion-news-analyst-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/1469571-pembina-plus-4_3-percent-on-pipeline-expansion-news-analyst-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469511\" data-ts=\"1387305510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGCO\" target=\"_blank\">AGCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469511-investor-meeting-doesnt-go-well-for-agco\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investor meeting doesn&#39;t go well for AGCO</a></h4><ul>\n<li>The announcement of a $500M share repurchase program isn't enough to save the day for AGCO (<a href=\"https://seekingalpha.com/symbol/AGCO\" title=\"AGCO Corporation\">AGCO</a> <font color=\"red\">-4.4%</font>) after management - at this morning's Investor Meeting - expects headwinds to hitting $6 per share in earnings this year, and sees $6/share as likely in 2014.</li>\n<li>Industry unit tractor sales are expected to fall 0-5% in North America, 5% in South America (amid an early end to Brazilian price supports), and 0-5% in Western Europe.</li>\n<li>Presentation slides <a href=\"http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjE1MzU5fENoaWxkSUQ9LTF8VHlwZT0z&amp;t=1\" target=\"_blank\">set #1</a>, <a href=\"http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjE1MzU4fENoaWxkSUQ9LTF8VHlwZT0z&amp;t=1\" target=\"_blank\">set #2</a>\n</li>\n<li>Deere (<a href=\"https://seekingalpha.com/symbol/DE\" title=\"Deere &amp; Company\">DE</a> <font color=\"red\">-0.6%</font>) slips a bit, but AGCO <a href=\"https://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1387314000000&amp;chddm=95013&amp;chls=IntervalBasedLine&amp;cmpto=NYSE:AGCO&amp;cmptdms=0&amp;q=NYSE:DE&amp;ntsp=0&amp;ei=mJmwUpDlIsu40AGuhgE&amp;authuser=1\" target=\"_blank\">has outperformed</a> by more than 1,500 basis points this year.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469511\" data-linked=\"Investor meeting doesn&#39;t go well for AGCO\" data-tweet=\"$AGCO $AGCO $DE - Investor meeting doesn&#39;t go well for AGCO https://seekingalpha.com/news/1469511-investor-meeting-doesnt-go-well-for-agco?source=tweet\" data-url=\"https://seekingalpha.com/news/1469511-investor-meeting-doesnt-go-well-for-agco\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469501\" data-ts=\"1387305334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLXP\" target=\"_blank\">SLXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469501-tuesdays-healthcare-upgrades-downgrades-and-initiations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tuesday&#39;s healthcare upgrades, downgrades, and initiations</a></h4><ul>\n<li>Salix Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/SLXP\" title=\"Salix Pharmaceuticals, Ltd.\">SLXP</a> <font color=\"red\">-0.2%</font>) <a href=\"http://www.streetinsider.com/Upgrades/Stifel+Nicolaus+Upgrades+Salix+Pharmaceuticals+%28SLXP%29+to+Buy/8984427.html\" target=\"_blank\">upgraded</a> to Buy from Hold at Stifel. Price target is $108.</li>\n<li>Medtronic (<a href=\"https://seekingalpha.com/symbol/MDT\" title=\"Medtronic plc\">MDT</a> <font color=\"green\">+0.3%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8984422\" target=\"_blank\">upgraded</a> to Buy from Neutral at Goldman. Price target hiked (by a buck) to $66.</li>\n<li>CareFusion (<a href=\"https://seekingalpha.com/symbol/CFN\" title=\"CareFusion Corporation\">CFN</a> <font color=\"red\">-3%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8984558\" target=\"_blank\">cut</a> to sell from Neutral at Goldman. Price target is $36.</li>\n<li>Ocera Therapeutics (<a href=\"https://seekingalpha.com/symbol/OCRX\" title=\"Ocera Therapeutics, Inc.\">OCRX</a> <font color=\"red\">-0.4%</font>) <a href=\"http://www.streetinsider.com/news.php?id=8984890\" target=\"_blank\">initiated</a> at Outperform at Cowen.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469501\" data-linked=\"Tuesday&#39;s healthcare upgrades, downgrades, and initiations\" data-tweet=\"$SLXP $SLXP $MDT - Tuesday&#39;s healthcare upgrades, downgrades, and initiations https://seekingalpha.com/news/1469501-tuesdays-healthcare-upgrades-downgrades-and-initiations?source=tweet\" data-url=\"https://seekingalpha.com/news/1469501-tuesdays-healthcare-upgrades-downgrades-and-initiations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469451\" data-ts=\"1387304224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469451-spectrum-pharma-falls-after-announcing-private-placement-of-convertible-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Spectrum Pharma falls after announcing private placement of convertible notes</a></h4><ul>\n<li>Spectrum Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/SPPI\" title=\"Spectrum Pharmaceuticals, Inc.\">SPPI</a> <font color=\"red\">-8.5%</font>) slides after Monday evening's announcement that the company intends to offer $100M in convertible notes.</li>\n<li>SPPI also says it intends to \"enter into convertible note hedge transactions and separate       warrant transactions with one or more financial institutions, which may       include the initial purchasers or their respective affiliates in order to reduce the potential dilution to       the common stock.\"</li>\n<li>Notes offered in the private placement will be sold to \"qualified institutional buyers.\" (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469451\" data-linked=\"Spectrum Pharma falls after announcing private placement of convertible notes\" data-tweet=\"$SPPI - Spectrum Pharma falls after announcing private placement of convertible notes https://seekingalpha.com/news/1469451-spectrum-pharma-falls-after-announcing-private-placement-of-convertible-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/1469451-spectrum-pharma-falls-after-announcing-private-placement-of-convertible-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469401\" data-ts=\"1387302889\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVLT\" target=\"_blank\">CVLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469401-commvault-jumps-following-bullish-piper-note-symantec-up-slightly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CommVault jumps following bullish Piper note; Symantec up slightly</a></h4><ul>\n<li>Piper's Andrew Nowinski is reiterating an Overweight and $96 PT for CommVault (<a href=\"https://seekingalpha.com/symbol/CVLT\" title=\"CommVault Systems, Inc.\">CVLT</a> <font color=\"green\">+7.7%</font>), and argues several investor concerns are misplaced.</li>\n<li>Nowinski chalks up recent comments from COO Al Bunte about being slightly behind plan for FY14 (ends March '14) as being \"more reflective of the overall tech spending environment\" than any company-specific issues, and still thinks CommVault is on track to meet its FY14 outlook. The company stated on its FQ2 CC (<a href=\"https://seekingalpha.com/article/1782832-commvault-systems-management-discusses-q2-2014-results-earnings-call-transcript\" target=\"_blank\">transcript</a>) it's comfortable with consensus estimates.</li>\n<li>Nowinski also: 1) Dismisses the threat posed by a pending refresh for Symantec's (<a href=\"https://seekingalpha.com/symbol/SYMC\" title=\"Symantec Corporation\">SYMC</a> <font color=\"green\">+1.2%</font>) <a href=\"http://www.symantec.com/netbackup\" target=\"_blank\">NetBackup suite</a>, arguing none of the new features provided are reasons for concern. 2) Calls CommVault's high-teens revenue growth target \"very doable,\" given share gains, new analytics features, and improving cloud service provider penetration. 3) Thinks price cut fears are unwarranted, particularly since CommVault already undercuts Symantec by 20%-25%.</li>\n<li>Before today's move, CommVault had been down YTD in what has been a very good year for tech stocks. <a href=\"https://seekingalpha.com/currents/post/1365382\" target=\"_blank\">Shares fell</a> following October's FQ2 report, in part due to worries about slowing deferred revenue growth.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469401\" data-linked=\"CommVault jumps following bullish Piper note; Symantec up slightly\" data-tweet=\"$CVLT $CVLT $NLOK - CommVault jumps following bullish Piper note; Symantec up slightly https://seekingalpha.com/news/1469401-commvault-jumps-following-bullish-piper-note-symantec-up-slightly?source=tweet\" data-url=\"https://seekingalpha.com/news/1469401-commvault-jumps-following-bullish-piper-note-symantec-up-slightly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469391\" data-ts=\"1387302753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHLDQ\" target=\"_blank\">SHLDQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469391-sears-holdings-takes-some-shots-from-former-exec\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sears Holdings takes some shots from former exec</a></h4><ul> <li>Former Sears Canada (SHLD) CEO Mark Cohen didn't mince words this morning on CNBC today on how he feels about Eddie Lampert.</li> <li>Lampert \"essentially killed\" the company and has put it in a <a href=\"https://twitter.com/carlquintanilla/status/412982790590705664\" target=\"_blank\">death spiral,</a> notes Cohen.</li> <li>Cohen's replacement seems to be playing ball with Lampert's liquidation plan. The current Sears Canada CEO told Bloomberg he sees more <a href=\"http://www.bloomberg.com/news/2013-12-17/sears-may-close-more-stores-amid-urban-retreat-corporate.html\" target=\"_blank\">opportunities</a> for store closures in the nation.</li><li>Actions speaking louder than words for the day:&nbsp;SHDL&nbsp;<font color='green'>+3.2%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1469391\" data-linked=\"Sears Holdings takes some shots from former exec\" data-tweet=\"$SHLDQ - Sears Holdings takes some shots from former exec https://seekingalpha.com/news/1469391-sears-holdings-takes-some-shots-from-former-exec?source=tweet\" data-url=\"https://seekingalpha.com/news/1469391-sears-holdings-takes-some-shots-from-former-exec\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469361\" data-ts=\"1387302331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469361-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Top 10 Gainers:</b> <a href='https://seekingalpha.com/symbol/MEIL' title='Methes Energies International Ltd.'>OTC:MEIL</a> <font color='green'>+53%</font>. KFN <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BWEN' title='Broadwind Energy, Inc.'>BWEN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/STXS' title='Stereotaxis, Inc.'>STXS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/RICK' title='RCI Hospitality Holdings, Inc.'>RICK</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/KOPN' title='Kopin Corporation'>KOPN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ADEP' title='Adept Technology, Inc.'>ADEP</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/IDIX' title='Idenix Pharmaceuticals, Inc.'>IDIX</a> <font color='green'>+11%</font>.</li><li><b>Top 10 Losers:</b> TRGT <font color='red'>-31%</font>. <a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/CBMX' title='CombiMatrix Corporation'>CBMX</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/DYSL' title='Dynasil Corporation of America'>DYSL</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ENZY' title='Enzymotec Ltd.'>ENZY</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/TELOZ' title='TEL Offshore Trust'>OTCPK:TELOZ</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ADAT' title='Authentidate Holding Corp.'>ADAT</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DRD' title='DRDGOLD Limited'>DRD</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469361\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MEIL $KKR $IRBT - Midday Gainers / Losers https://seekingalpha.com/news/1469361-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1469361-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469341\" data-ts=\"1387302029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCFT\" target=\"_blank\">HCFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469341-five-oaks-launches-preferred-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five Oaks launches preferred offering</a></h4><ul><li>There's one mortgage REIT looking to add to its portfolio as Five Oaks Investment (OAKS <font color=\"red\">-2.9%</font>) sets an offering of preferred stock, with the intention of buying non-agency MBS with the proceeds.</li></ul><div class=\"tiny-share-widget\" data-id=\"1469341\" data-linked=\"Five Oaks launches preferred offering\" data-tweet=\"$HCFT - Five Oaks launches preferred offering https://seekingalpha.com/news/1469341-five-oaks-launches-preferred-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/1469341-five-oaks-launches-preferred-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469331\" data-ts=\"1387301946\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469331-nucor-s-disappointing-guidance-is-good-news-for-ak-steel-us-steel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucor\u2019s disappointing guidance is good news for AK Steel, US Steel</a></h4><ul>     <li>Nucor\u2019s (<a href=\"https://seekingalpha.com/symbol/NUE\" title=\"Nucor Corporation\">NUE</a> <font color=\"red\">-2%</font>) <a href=\"https://seekingalpha.com/currents/post/1468691\" target=\"_blank\">downside Q4 guidance</a> mostly reflects its losing side bet on natural gas, and Citigroup\u2019s Brian Yu thinks the guidance has <a href=\"http://blogs.barrons.com/stockstowatchtoday/2013/12/17/is-nucors-disappointment-good-news-for-ak-steel-and-us-steel/\" target=\"_blank\">positive implications</a> for sheet producers AK Steel (<a href=\"https://seekingalpha.com/symbol/AKS\" title=\"AK Steel Holding Corp\">AKS</a> <font color=\"green\">+2%</font>), U.S. Steel (<a href=\"https://seekingalpha.com/symbol/X\" title=\"United States Steel Corporation\">X</a> <font color=\"green\">+0.5%</font>) and Steel Dynamics (<a href=\"https://seekingalpha.com/symbol/STLD\" title=\"Steel Dynamics, Inc.\">STLD</a> <font color=\"red\">-0.4%</font>).</li>     <li>NUE noted improved profitability from its sheet unit, despite the three-week planned outage at the Berkeley County mill, due to a series of price hikes; also, bar and structural mills saw weaker performance due to planned outages for upgrades at the SBQ mill in Norfolk and structural mill in Blytheville.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469331\" data-linked=\"Nucor\u2019s disappointing guidance is good news for AK Steel, US Steel\" data-tweet=\"$NUE $NUE $AKS - Nucor\u2019s disappointing guidance is good news for AK Steel, US Steel https://seekingalpha.com/news/1469331-nucor-s-disappointing-guidance-is-good-news-for-ak-steel-us-steel?source=tweet\" data-url=\"https://seekingalpha.com/news/1469331-nucor-s-disappointing-guidance-is-good-news-for-ak-steel-us-steel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469291\" data-ts=\"1387301044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRBT\" target=\"_blank\">IRBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469291-irobot-skyrockets-following-rj-upgrade-adept-also-rallying\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">iRobot skyrockets following RJ upgrade; Adept also rallying</a></h4><ul>\n<li>As far as tech momentum trades go, robots are apparently the new 3D printers. iRobot (<a href=\"https://seekingalpha.com/symbol/IRBT\" title=\"iRobot Corporation\">IRBT</a> <font color=\"green\">+17.9%</font>) is blasting off in the wake of a <a href=\"https://seekingalpha.com/currents/post/1468701\" target=\"_blank\">Raymond James upgrade</a> that comes shortly after Google confirmed the acquisition of defense robot maker <a href=\"https://seekingalpha.com/currents/post/1465331\" target=\"_blank\">Boston Dynamics</a>, and fellow robot maker Adept Technology (<a href=\"https://seekingalpha.com/symbol/ADEP\" title=\"Adept Technology, Inc.\">ADEP</a> <font color=\"green\">+8%</font>) is also up sharply.</li>\n<li>Interestingly, RJ's upgrade doesn't center around Google or even iRobot's defense/security robot ops (just 8% of Q3 revenue), but rather its new <a href=\"http://store.irobot.com/product/index.jsp?productId=28516906&amp;cp=2804605.3334619.2501652&amp;s=A-ProductAge&amp;parentPage=family\" target=\"_blank\">Roomba 800 series</a> vacuum robots (expected to boost 2014 sales), and its <a href=\"http://store.irobot.com/family/index.jsp?categoryId=23314286&amp;s=A-ProductAge\" target=\"_blank\">Braava</a> mopping robots (recently <a href=\"https://seekingalpha.com/currents/post/1238392\" target=\"_blank\">became available</a> in North America).</li>\n<li>\n<a href=\"https://seekingalpha.com/currents/post/1467241\" target=\"_blank\">Sidoti</a> upgraded iRobot yesterday. 10% of the company's float was shorted as of Nov. 29.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469291\" data-linked=\"iRobot skyrockets following RJ upgrade; Adept also rallying\" data-tweet=\"$IRBT $IRBT $ADEP - iRobot skyrockets following RJ upgrade; Adept also rallying https://seekingalpha.com/news/1469291-irobot-skyrockets-following-rj-upgrade-adept-also-rallying?source=tweet\" data-url=\"https://seekingalpha.com/news/1469291-irobot-skyrockets-following-rj-upgrade-adept-also-rallying\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469281\" data-ts=\"1387300899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGG-OLD\" target=\"_blank\">CGG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469281-cgg-minus-16_5-percent-after-lowering-2013-ebit-guidance-warning-of-project-delays\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CGG -16.5% after lowering 2013 EBIT guidance, warning of project delays</a></h4><ul>     <li>CGG (<a href=\"https://seekingalpha.com/symbol/CGG-OLD\" title=\"CGG\">CGG-OLD</a> <font color=\"red\">-16.5%</font>) shares sink after the oil services <a href=\"http://finance.yahoo.com/news/cgg-implement-strategic-phase-074844877.html\" target=\"_blank\">revises its FY 2013 guidance lower</a> to $400M-$420M and plans to carry out a rebalancing of its asset portfolio in a move to cut costs and boost margins.</li>     <li>CGG says it is \"operating in difficult market conditions\" as clients delay their awards of large projects in the Marine Acquisition business; even though the company expect its Q4 fleet production rate to remain above 90%, the availability rate will be ~80%.</li>     <li>Separately, CGG announces a multi-client <a href=\"http://finance.yahoo.com/news/cgg-spectrum-announce-large-multi-063405908.html\" target=\"_blank\">survey program offshore Brazil</a> to focus on a  large proportion of open acreage in the Foz do Amazonas  Basin.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469281\" data-linked=\"CGG -16.5% after lowering 2013 EBIT guidance, warning of project delays\" data-tweet=\"$CGG-OLD - CGG -16.5% after lowering 2013 EBIT guidance, warning of project delays https://seekingalpha.com/news/1469281-cgg-minus-16_5-percent-after-lowering-2013-ebit-guidance-warning-of-project-delays?source=tweet\" data-url=\"https://seekingalpha.com/news/1469281-cgg-minus-16_5-percent-after-lowering-2013-ebit-guidance-warning-of-project-delays\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469271\" data-ts=\"1387300630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469271-teva-settles-with-pfizer-to-offer-generic-viagra-in-2017\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva settles with Pfizer; to offer generic Viagra in 2017</a></h4><ul><li>Teva Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/TEVA\" title=\"Teva Pharmaceutical Industries Limited\">TEVA</a> <font color=\"red\">-0.1%</font>) will be allowed to launch a generic version of Viagra on Dec. 11, 2017 (or earlier under certain circumstances) following a settlement of Pfizer's (<a href=\"https://seekingalpha.com/symbol/PFE\" title=\"Pfizer Inc.\">PFE</a> <font color=\"red\">-0.1%</font>) patent litigation case against the company. Teva will pay Pfizer a royalty for a license to produce the generic version. Other terms of the settlement are confidential.</li></ul><div class=\"tiny-share-widget\" data-id=\"1469271\" data-linked=\"Teva settles with Pfizer; to offer generic Viagra in 2017\" data-tweet=\"$TEVA $TEVA $PFE - Teva settles with Pfizer; to offer generic Viagra in 2017 https://seekingalpha.com/news/1469271-teva-settles-with-pfizer-to-offer-generic-viagra-in-2017?source=tweet\" data-url=\"https://seekingalpha.com/news/1469271-teva-settles-with-pfizer-to-offer-generic-viagra-in-2017\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469261\" data-ts=\"1387300060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPQ\" target=\"_blank\">HPQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469261-jpmorgans-h-p-upgrade-valuation-cash-flow-growth-praised\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan&#39;s H-P upgrade: Valuation, cash flow growth praised</a></h4><ul><li>JPMorgan's <a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+JPMorgan+Upgrades+Hewlett-Packard+%28HPQ%29+to+Overweight/8984413.html\" target=\"_blank\">Mark Moskowitz</a>, who has <a href=\"https://seekingalpha.com/currents/post/1468701\" target=\"_blank\">upgraded</a> H-P (<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a> <font color='green'>+2.4%</font>) to Overweight and raised his PT to $35 from $30, thinks the IT giant is capable of generating annual free cash flow of more than $8B. That's a level well above H-P's FY14 (ends Oct. '14) <a href=\"https://seekingalpha.com/currents/post/1321182\" target=\"_blank\">FCF guidance range</a> of $6B-$6.5B.</li><li>Moskowitz also sees room for further multiple expansion: He thinks H-P, which currently trades at 7.5x FY14E EPS, <a href=\"https://twitter.com/thenotablecalls/status/412954206799003648\" target=\"_blank\">could eventually trade</a> at 8.5x-9.5x earnings.</li><li>Shares are <strong><font color='green'>up 93%</font></strong> YTD, and not far removed from their 52-week high of $28.70.</li></ul><div class=\"tiny-share-widget\" data-id=\"1469261\" data-linked=\"JPMorgan&#39;s H-P upgrade: Valuation, cash flow growth praised\" data-tweet=\"$HPQ - JPMorgan&#39;s H-P upgrade: Valuation, cash flow growth praised https://seekingalpha.com/news/1469261-jpmorgans-h-p-upgrade-valuation-cash-flow-growth-praised?source=tweet\" data-url=\"https://seekingalpha.com/news/1469261-jpmorgans-h-p-upgrade-valuation-cash-flow-growth-praised\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469211\" data-ts=\"1387299461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SARA\" target=\"_blank\">SARA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469211-saratoga-says-2_74m-boe-of-proved-reserves-at-new-gulf-of-mexico-projects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Saratoga says 2.74M boe of proved reserves at new Gulf of Mexico projects</a></h4><ul>     <li>Saratoga Resources (<a href=\"https://seekingalpha.com/symbol/SARA-OLD\" title=\"Saratoga Resources, Inc.\">SARA</a> <font color=\"green\">+4.9%</font>) says independent audited reserve estimates on two of its shallow Gulf of Mexico leases, awarded earlier this year, show combined proved undeveloped reserves totaling 2.74M boe (46% oil), with estimated present worth values using a discount rate of 10% of $37.2M.</li>     <li>The leases cover 19,814 gross and net acres in four lease blocks, and are located in the shallow Gulf  of Mexico in water depths  of 13-79 ft., close to existing infrastructure.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1469211\" data-linked=\"Saratoga says 2.74M boe of proved reserves at new Gulf of Mexico projects\" data-tweet=\"$SARA $SARA-OLD - Saratoga says 2.74M boe of proved reserves at new Gulf of Mexico projects https://seekingalpha.com/news/1469211-saratoga-says-2_74m-boe-of-proved-reserves-at-new-gulf-of-mexico-projects?source=tweet\" data-url=\"https://seekingalpha.com/news/1469211-saratoga-says-2_74m-boe-of-proved-reserves-at-new-gulf-of-mexico-projects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469081\" data-ts=\"1387297649\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBMX\" target=\"_blank\">CBMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469081-combimatrix-prices-offering-shares-fall\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CombiMatrix prices offering, shares fall</a></h4><ul>\n<li>Shares of CombiMatrix (<a href=\"https://seekingalpha.com/symbol/CBMX\" title=\"CombiMatrix Corporation\">CBMX</a> <font color=\"red\">-20%</font>) are off sharply after the company priced a $12M offering of Series D convertible preferred and warrants.</li>\n<li>The units priced at $1,000 each and contain one Series D share (convertible to 485.4369 shares of common at $2.06) and a warrant for another 485.4369 shares at $3.12 each.</li>\n<li>Net proceeds: $10.8M. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469081\" data-linked=\"CombiMatrix prices offering, shares fall\" data-tweet=\"$CBMX - CombiMatrix prices offering, shares fall https://seekingalpha.com/news/1469081-combimatrix-prices-offering-shares-fall?source=tweet\" data-url=\"https://seekingalpha.com/news/1469081-combimatrix-prices-offering-shares-fall\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1469051\" data-ts=\"1387296791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YGE\" target=\"_blank\">YGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1469051-yingli-rallies-after-announcing-major-algerian-contracts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yingli rallies after announcing major Algerian contracts</a></h4><ul>\n<li>Yingli (<a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a> <font color=\"green\">+6.3%</font>), in partnership with two other Chinese firms, has won 233MW worth of Algerian solar project contracts from a unit of state-owned utility Sonelgaz. Construction will start next month, and is expected to be finished in eight months. (PR)</li>\n<li>Separately, Yingli says its modules will be exempt from EU anti-dumping and anti-subsidy duties as part of <a href=\"http://www.bloomberg.com/news/2013-12-02/u-nations-approve-pact-with-china-on-solar-panel-trade.html\" target=\"_blank\">an agreement</a> reached between EU and Chinese regulators (<a href=\"https://seekingalpha.com/currents/post/1191312\" target=\"_blank\">previous</a>). The deal calls for participating Chinese solar exporters (including Yingli) to agree to a minimum module price of \u20ac0.56/watt, and caps solar imports from China at 7GW.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1469051\" data-linked=\"Yingli rallies after announcing major Algerian contracts\" data-tweet=\"$YGE - Yingli rallies after announcing major Algerian contracts https://seekingalpha.com/news/1469051-yingli-rallies-after-announcing-major-algerian-contracts?source=tweet\" data-url=\"https://seekingalpha.com/news/1469051-yingli-rallies-after-announcing-major-algerian-contracts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468961\" data-ts=\"1387295705\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FST\" target=\"_blank\">FST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468961-forest-oil-minus-4_3-percent-on-baird-downgrade-on-eagle-ford-concerns\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forest Oil -4.3% on Baird downgrade on Eagle Ford concerns</a></h4><ul>     <li>Forest Oil (<a href=\"https://seekingalpha.com/symbol/FST\" title=\"Forest Oil Corporation\">FST</a> <font color=\"red\">-4.3%</font>) is <a href=\"http://www.streetinsider.com/Downgrades/Baird+Downgrades+Forest+Oil+%28FST%29+to+Neutral/8984933.html\" target=\"_blank\">downgraded</a> to Neutral from Outperform with a $4 price target, down from $7, at Robert W. Baird, due to concerns around returns and future growth.</li>     <li>Given FST's sub-par rates of return and creeping leverage, Baird believes it will be difficult for FST to achieve robust growth rates going forward; while acknowledging recent share underperformance, the firm doesn't see any significant upside catalysts.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1468961\" data-linked=\"Forest Oil -4.3% on Baird downgrade on Eagle Ford concerns\" data-tweet=\"$FST - Forest Oil -4.3% on Baird downgrade on Eagle Ford concerns https://seekingalpha.com/news/1468961-forest-oil-minus-4_3-percent-on-baird-downgrade-on-eagle-ford-concerns?source=tweet\" data-url=\"https://seekingalpha.com/news/1468961-forest-oil-minus-4_3-percent-on-baird-downgrade-on-eagle-ford-concerns\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468921\" data-ts=\"1387294853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468921-puma-rallies-as-bofa-gets-more-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma rallies as BofA gets (more) bullish</a></h4><ul>\n<li>Puma Biotechnology (<a href=\"https://seekingalpha.com/symbol/PBYI\" title=\"Puma Biotechnology, Inc.\">PBYI</a> <font color=\"green\">+9.6%</font>) races out of the gate to trade near the $100 per share mark.</li>\n<li>Helping the cause is BofA, where analysts are \"<a href=\"https://twitter.com/bradloncar/status/412966769997787136/photo/1\" target=\"_blank\">taking the opportunity</a> to increase [their] price objective following [an] in depth adjuvant breast cancer analysis.\"</li>\n<li>BofA calls the risk reward going into an expected H1 2014 breast cancer read-out \"one of the most compelling buying opportunities in biotech.\"</li>\n<li>How's this for optimistic: Price target hiked to $118 (from $87), but BofA still \"sees an additional ~$100/share upside potential in a positive scenario [and] an additional $40-50/share upside\" in the event data on Her2 mutant cancer is positive.</li>\n<li>For reference and context, see <a href=\"https://seekingalpha.com/currents/search?query=neratinib\" target=\"_blank\">here</a>.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468921\" data-linked=\"Puma rallies as BofA gets (more) bullish\" data-tweet=\"$PBYI - Puma rallies as BofA gets (more) bullish https://seekingalpha.com/news/1468921-puma-rallies-as-bofa-gets-more-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/1468921-puma-rallies-as-bofa-gets-more-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468831\" data-ts=\"1387293352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XSPA\" target=\"_blank\">XSPA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468831-vringo-obtains-german-base-station-injunction-against-zte\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vringo obtains German base station injunction against ZTE</a></h4><ul><li>A German court <a href=\"http://online.wsj.com/article/BT-CO-20131217-703731.html?dsk=y\" target=\"_blank\">has ruled</a> ZTE base stations are infringing a European Vringo (VRNG <font color='green'>+1.9%</font>) patent, and has placed an injunction on their sale. ZTE has also been ordered to pay damages.</li><li>Look for ZTE to appeal the ruling; the company has already filed an action in a German patent court requesting the Vringo patent in question be nullified.</li><li>Vringo obtained <a href=\"https://seekingalpha.com/currents/post/1428401\" target=\"_blank\">an Indian injunction</a> against ZTE phones and infrastructure gear ruled to be infringing a patent considered standards-essential for cdma2000 3G networks.</li></ul><div class=\"tiny-share-widget\" data-id=\"1468831\" data-linked=\"Vringo obtains German base station injunction against ZTE\" data-tweet=\"$XSPA - Vringo obtains German base station injunction against ZTE https://seekingalpha.com/news/1468831-vringo-obtains-german-base-station-injunction-against-zte?source=tweet\" data-url=\"https://seekingalpha.com/news/1468831-vringo-obtains-german-base-station-injunction-against-zte\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468821\" data-ts=\"1387293334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468821-southeast-asia-rallies-ahead-of-fed-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southeast Asia rallies ahead of Fed meeting</a></h4><ul><li>Thai (<a href='https://seekingalpha.com/symbol/thd' title='iShares MSCI Thailand Capped ETF'>THD</a>, <a href='https://seekingalpha.com/symbol/tf' title='Thai Capital Fund'>TF</a>, <a href='https://seekingalpha.com/symbol/ttf' title='Thai Fund'>TTF</a>)&nbsp;and Indonesian (<a href='https://seekingalpha.com/symbol/idx' title='Market Vectors Indonesia Index ETF'>IDX</a>, <a href='https://seekingalpha.com/symbol/eido' title='iShares MSCI Indonesia ETF'>EIDO</a>, <a href='https://seekingalpha.com/symbol/idxj' title='Market Vectors Indonesia Small Cap ETF'>IDXJ</a>) shares rebound from multi-month lows, rising <font color='green'>0.7%</font> and <font color='green'>1.4%</font>, respectively.</li><li>Also rallying today are Philippine shares (<a href='https://seekingalpha.com/symbol/ephe' title='iShares MSCI Philippines ETF'>EPHE</a>), up <font color='green'>2%</font> in Manila.</li><li>Southeast Asian investors will be watching the Fed closely for hints about the taper, as many commentators still believe emerging markets will suffer once the FOMC&nbsp;begins to pare its asset purchases.</li></ul><div class=\"tiny-share-widget\" data-id=\"1468821\" data-linked=\"Southeast Asia rallies ahead of Fed meeting\" data-tweet=\"$THD $TF-OLD $TTF - Southeast Asia rallies ahead of Fed meeting https://seekingalpha.com/news/1468821-southeast-asia-rallies-ahead-of-fed-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/1468821-southeast-asia-rallies-ahead-of-fed-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468761\" data-ts=\"1387292364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468761-compass-point-downgrades-2-homebuilders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Compass Point downgrades 2 homebuilders</a></h4><ul>\n<li>The homebuilders (<a href=\"https://seekingalpha.com/symbol/ITB\" title=\"iShares U.S. Home Construction ETF\">ITB</a> <font color=\"red\">-0.5%</font>) are under some early pressure as Compass Point downgrades KB Home (<a href=\"https://seekingalpha.com/symbol/KBH\" title=\"KB Home\">KBH</a> <font color=\"red\">-1.8%</font>) to Sell and D.R. Horton (<a href=\"https://seekingalpha.com/symbol/DHI\" title=\"D. R. Horton Inc.\">DHI</a> <font color=\"red\">-1.3%</font>) to Hold. KB is scheduled to release FQ4 results before the open on Thursday.</li>\n<li>Related ETF: <a href=\"https://seekingalpha.com/symbol/XHB\" title=\"SPDR Homebuilders ETF\">XHB</a>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468761\" data-linked=\"Compass Point downgrades 2 homebuilders\" data-tweet=\"$KBH $ITB $KBH - Compass Point downgrades 2 homebuilders https://seekingalpha.com/news/1468761-compass-point-downgrades-2-homebuilders?source=tweet\" data-url=\"https://seekingalpha.com/news/1468761-compass-point-downgrades-2-homebuilders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468731\" data-ts=\"1387292122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEMP\" target=\"_blank\">CEMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468731-jefferies-hikes-target-on-cempra\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies hikes target on Cempra</a></h4><ul>\n<li>Jefferies is out <a href=\"http://www.streetinsider.com/Analyst+Comments/Cempra+%28CEMP%29+Target+Raised+to+%2416+at+Jefferies/8985145.html\" target=\"_blank\">reiterating</a> a Buy rating on Cempra (<a href=\"https://seekingalpha.com/symbol/CEMP\" title=\"Cempra, Inc.\">CEMP</a> <font color=\"red\">-9.4%</font>) on the heels of Monday night's solithromycin and Taksta update.</li>\n<li>The company notes that it has initiated a Phase 3 study of Solitaire-IV in CABP and says it expects a top-line read-out from Phase 3 Solitaire-Oral in \"mid-2014.\" (PR)</li>\n<li>Analyst Eun Yang says a \"potential commercial partnership for solithromycin is likely after [the] first Phase 3 data in CABP\" an event he expects will \"offer meaningful upside from current levels.\"</li>\n<li>Price target raised to $16 from $14.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468731\" data-linked=\"Jefferies hikes target on Cempra\" data-tweet=\"$CEMP - Jefferies hikes target on Cempra https://seekingalpha.com/news/1468731-jefferies-hikes-target-on-cempra?source=tweet\" data-url=\"https://seekingalpha.com/news/1468731-jefferies-hikes-target-on-cempra\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468701\" data-ts=\"1387291010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468701-a-roundup-of-tech-ratings-changes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">A roundup of tech ratings changes</a></h4><ul><li>Facebook (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='green'>+1.9%</font>) has been upgraded to Positive by Susquehanna. The upgrade comes as the company begins a news feed <a href=\"https://seekingalpha.com/currents/post/1467921\" target=\"_blank\">video ad test</a>.</li><li>H-P (<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a> <font color='green'>+1.9%</font>) has been upgraded to Overweight by JPMorgan.</li><li>Seagate (<a href='https://seekingalpha.com/symbol/STX' title='Seagate Technology'>STX</a> <font color='green'>+1.2%</font>) and Western Digital have been upgraded to Overweight by JPMorgan. Citi upgraded the hard drive giants to Buy <a href=\"https://seekingalpha.com/currents/post/1463801\" target=\"_blank\">last week</a>.</li><li>iRobot (<a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='green'>+9.8%</font>) has been upgraded to Strong Buy by Raymond James.</li><li>500.com (<a href='https://seekingalpha.com/symbol/WBAI' title='500.com Limited'>WBAI</a> <font color='red'>-2.3%</font>) has been assigned neutral ratings by Deutsche and Piper on underwriter coverage day.</li></ul><div class=\"tiny-share-widget\" data-id=\"1468701\" data-linked=\"A roundup of tech ratings changes\" data-tweet=\"$FB $FB $HPQ - A roundup of tech ratings changes https://seekingalpha.com/news/1468701-a-roundup-of-tech-ratings-changes?source=tweet\" data-url=\"https://seekingalpha.com/news/1468701-a-roundup-of-tech-ratings-changes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468641\" data-ts=\"1387290493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATHX\" target=\"_blank\">ATHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468641-athersys-gets-orphan-designation-in-the-eu-for-gvhd-prophylactic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athersys gets Orphan designation in the EU for GvHD prophylactic</a></h4><ul>\n<li>Athersys (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ATHX\" title=\"Athersys, Inc.\">ATHX</a>) jumps<font color=\"green\"> 6%</font> before the bell.</li>\n<li>The EMA has granted an Orphan Drug designation for the company's MultiStem therapy for the prevention of graft-versus-host disease in patients undergoing HSC transplants.</li>\n<li>The therapy also has Orphan status in the U.S. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468641\" data-linked=\"Athersys gets Orphan designation in the EU for GvHD prophylactic\" data-tweet=\"$ATHX - Athersys gets Orphan designation in the EU for GvHD prophylactic https://seekingalpha.com/news/1468641-athersys-gets-orphan-designation-in-the-eu-for-gvhd-prophylactic?source=tweet\" data-url=\"https://seekingalpha.com/news/1468641-athersys-gets-orphan-designation-in-the-eu-for-gvhd-prophylactic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468581\" data-ts=\"1387289515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCBK\" target=\"_blank\">HCBK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468581-hudson-city-and-m-and-t-extend-time-for-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hudson City and M&amp;T extend time for merger</a></h4><ul>\n<li>Hudson City Bancorp (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HCBK\" title=\"Hudson City Bancorp, Inc.\">HCBK</a>) and M&amp;T Bank (NYSE:<a href=\"https://seekingalpha.com/symbol/MTB\" title=\"M&amp;T Bank Corporation\">MTB</a>) agree to extend the time to complete their merger until December 31, 2014.</li>\n<li>To review, M&amp;T agreed to buy Hudson City in August 2012, but regulators - <a href=\"https://seekingalpha.com/currents/post/1228202\" target=\"_blank\">displeased with</a> M&amp;T's money laundering policies - put the deal on ice, chilling not just this transaction, but a lot of other possible regional bank M&amp;A.</li>\n<li>\"M&amp;T has received no assurance from the Federal Reserve as to whether or when the Federal Reserve will approve the merger.  However, M&amp;T and Hudson City believe that the earliest time the merger could be completed is in the latter half of 2014.\"</li>\n<li>Hudson City CEO Ronald Hermance: \"While all parties are disappointed that the transaction is delayed further, we are gratified that M&amp;T continues to see the value in the Hudson City franchise.  Our Board of Directors continues to believe that the M&amp;T transaction is ultimately in the best interest of the company and our shareholders, but is also committed to diversifying our business model by continuing to pursue our Strategic Plan.\"</li>\n<li>HCBK <font color=\"red\">-1.2%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468581\" data-linked=\"Hudson City and M&amp;T extend time for merger\" data-tweet=\"$HCBK $HCBK $MTB - Hudson City and M&amp;T extend time for merger https://seekingalpha.com/news/1468581-hudson-city-and-m-and-t-extend-time-for-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/1468581-hudson-city-and-m-and-t-extend-time-for-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468571\" data-ts=\"1387289511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468571-premarket-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers</a></h4><ul><li><b>Gainers:</b> KFN <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='green'>+14%</font>. BIOD <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ATHX' title='Athersys, Inc.'>ATHX</a> <font color='green'>+7%</font>. VRNG <font color='green'>+6%</font>.</li><li><b>Losers:</b> TRGT <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CBMX' title='CombiMatrix Corporation'>CBMX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/NWBO' title='Northwest Biotherapeutics, Inc.'>OTCQB:NWBO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ENT' title='Global Eagle Entertainment, Inc.'>ENT</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"1468571\" data-linked=\"Premarket Gainers / Losers\" data-tweet=\"$KKR $FTR $ALBO - Premarket Gainers / Losers https://seekingalpha.com/news/1468571-premarket-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/1468571-premarket-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468501\" data-ts=\"1387288684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWBO\" target=\"_blank\">NWBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468501-feuerstein-article-hits-northwest-biotherapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Feuerstein article hits Northwest Biotherapeutics</a></h4><ul>\n<li>Shares of Northwest Biotherapeutics (<a href=\"https://seekingalpha.com/symbol/NWBO\" title=\"Northwest Biotherapeutics, Inc.\">OTCQB:NWBO</a>) are suffering, off<font color=\"red\"> 7% </font>in premarket action.</li>\n<li>Not helping the cause is <em>TheStreet</em>'s Adam Feuerstein, who says DCVax \"<a href=\"http://www.thestreet.com/story/12156974/1/why-northwest-bios-dcvax-brain-tumor-vaccine-will-blow-up-just-like-immunocellulars-ict-107.html\" target=\"_blank\">will fail</a> just like ICT-107 failed because dendritic cancer vaccines are too weak to overcome cancer's  innate ability to overpower or evade the body's immune system.\"</li>\n<li>The thrust of the argument here is that positive data from early studies of the DCVax were misleading because the 20 brain cancer patients \"were handpicked for treatment.\"</li>\n<li>Feuerstein says the same was true of a small Phase 1 study of ImmunoCellular's ICT-107, which ended up missing its primary OS endpoint in a larger study (triggering a spectacular <a href=\"https://seekingalpha.com/currents/post/1460251\" target=\"_blank\">sell-off</a> last Wednesday).</li>\n<li>Feuerstein is responding to <a href=\"https://seekingalpha.com/article/1901331-why-northwest-biotherapeutics-is-different\" target=\"_blank\">an article</a> by SA contributor Josh Ginsburg who, on Monday, explained why he thinks NWBO \"is different.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468501\" data-linked=\"Feuerstein article hits Northwest Biotherapeutics\" data-tweet=\"$NWBO - Feuerstein article hits Northwest Biotherapeutics https://seekingalpha.com/news/1468501-feuerstein-article-hits-northwest-biotherapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/1468501-feuerstein-article-hits-northwest-biotherapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468471\" data-ts=\"1387288244\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468471-fuelcell-minus-12_3-percent-premarket-after-missing-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FuelCell -12.3% premarket after missing earnings</a></h4><ul>     <li>FuelCell Energy (NASDAQ:<a href=\"https://seekingalpha.com/symbol/FCEL\" title=\"FuelCell Energy, Inc.\">FCEL</a>) <font color=\"red\">-12.3%</font> premarket after posting a big miss on its <a href=\"https://seekingalpha.com/currents/post/1467821\" target=\"_blank\">FQ4 earnings</a> number but beating on revenues.</li>     <li>The $0.05/share loss was unchanged Y/Y and worse than the $0.03 loss in FQ3; for the fiscal year, the loss totaled $34.4M, slightly less than a year ago but FCEL hasn't posted an annual profit since 1997.</li>     <li>Total revenue jumped 56% to $55.2M, gross margin widened to 4.7% from 2.5%, and backlog totaled $355.4M at the end of the quarter vs. $318.9M a year ago.</li>     <li>FCEL expects customer acceptance of the Bridgeport fuel cell park during FQ1 to trigger the start of the associated $69M 15-year service contract and contribute to a quarterly increase in service revenues in FY 2014.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1468471\" data-linked=\"FuelCell -12.3% premarket after missing earnings\" data-tweet=\"$FCEL - FuelCell -12.3% premarket after missing earnings https://seekingalpha.com/news/1468471-fuelcell-minus-12_3-percent-premarket-after-missing-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/1468471-fuelcell-minus-12_3-percent-premarket-after-missing-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468461\" data-ts=\"1387287900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLF\" target=\"_blank\">HLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468461-herbalife-controversy-rages-as-stock-marches-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Herbalife controversy rages as stock marches higher</a></h4><ul>\n<li>SunTrust Robinson Humphrey's Michael Swartz is now <a href=\"http://www.streetinsider.com/Analyst+Comments/Herbalife+%28HLF%29+Re-Audit+Serves+as+%27Nail+in+the+Coffin%27+for+Shorts+-+SunTrust%3B+PT+Raised+to+%2485/8984671.html\" target=\"_blank\">more comfortable</a> with his Buy recommendation on shares of Herbalife (NYSE:<a href=\"https://seekingalpha.com/symbol/HLF\" title=\"Herbalife Ltd.\">HLF</a>) following Monday's re-audit news (see <a href=\"https://seekingalpha.com/currents/post/1467311\" target=\"_blank\">here</a> and <a href=\"https://seekingalpha.com/currents/post/1467351\" target=\"_blank\">here</a>).</li>\n<li>\"Considering PwC's intensive seven-month scrubbing-of-the-books in the  face of heightened media/public scrutiny, it could serve as a nail in  the coffin for the bear case,\" Swartz says, adding that although he is \"uncertain as to the ultimate size or timing,\" HLF probably \"has flexibility for a buyback in upwards of $1.5B, which could add $1+ to annualized EPS.\" Price target lifted to $85.</li>\n<li>Meanwhile, some commentators were quick to note that the re-audit had little to do with the bear case in the first place. Here's <a href=\"http://www.thestreet.com/story/12156500/1/greenberg-herbalife-audit-irrelevant-to-the-bigger-story.html\" target=\"_blank\">Herb Greenberg</a>: \"Let's not forget, the role of the auditor is to determine whether the  numbers are audited in accordance with GAAP, not to weigh in on the [pyramid scheme] controversy.\"</li>\n<li>Similarly, here's <a href=\"https://twitter.com/jimcramer/status/412685144869191680\" target=\"_blank\">Jim Cramer</a>: \"[I'm] just stating, frankly, the obvious \u2014 that the audit wasn't about Ponzi schemes.\"</li>\n<li>HLF <font color=\"green\">+1.8%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468461\" data-linked=\"Herbalife controversy rages as stock marches higher\" data-tweet=\"$HLF - Herbalife controversy rages as stock marches higher https://seekingalpha.com/news/1468461-herbalife-controversy-rages-as-stock-marches-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/1468461-herbalife-controversy-rages-as-stock-marches-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468451\" data-ts=\"1387287897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MMM\" target=\"_blank\">MMM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468451-3m-business-update-solid-guidance-dividend-hike-new-buyback-allowance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3M business update: Solid guidance, dividend hike, new buyback allowance</a></h4><ul> <li>3M (NYSE:<a href=\"https://seekingalpha.com/symbol/MMM\" title=\"3M Company\">MMM</a>) is out with an announcement and guidance in front of a meeting with institutional investors and analysts.</li> <li>The company says it maintains a long-term organic revenue target for 4%-6% growth and an EPS outlook of 9%-11% growth.</li> <li>For 2014, 3M sees EPS of $7.30-$7.55 vs. $7.40 consensus.</li> <li>A dividend payout increase of 35% and a plan to buy back $17B to $22B in shares is also outlined by execs.</li> <li><a href=\"http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&amp;c=80574&amp;eventID=5044297\" target=\"_blank\">3M Analyst meeting webcast</a></li> <li>MMM <font color=\"green\">+2.7%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"1468451\" data-linked=\"3M business update: Solid guidance, dividend hike, new buyback allowance\" data-tweet=\"$MMM - 3M business update: Solid guidance, dividend hike, new buyback allowance https://seekingalpha.com/news/1468451-3m-business-update-solid-guidance-dividend-hike-new-buyback-allowance?source=tweet\" data-url=\"https://seekingalpha.com/news/1468451-3m-business-update-solid-guidance-dividend-hike-new-buyback-allowance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468381\" data-ts=\"1387287017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALBO\" target=\"_blank\">ALBO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468381-biodel-inks-deal-with-becton-dickinson-for-injection-system\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biodel inks deal with Becton, Dickinson for injection system</a></h4><ul>\n<li>Biodel (BIOD) jumps<font color=\"green\"> 14%</font> in premarket trading.</li>\n<li>The company has inked a long-term supply deal with Becton, Dickinson (NYSE:<a href=\"https://seekingalpha.com/symbol/BDX\" title=\"Becton, Dickinson and Company\">BDX</a>) for exclusive rights to the BD Uniject SCF Disposable Auto-Disable Injection System.</li>\n<li>BIOD will leverage the device to serve the \"glucagon rescue treatment market by replacing antiquated, difficult, and  cumbersome multi-part kits with simple, convenient, portable therapies.\"</li>\n<li>In other words, the company is using the devices to deliver liquid glucagon for the treatment of hypoglycemia. (PR)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468381\" data-linked=\"Biodel inks deal with Becton, Dickinson for injection system\" data-tweet=\"$ALBO $ALBO $BDX - Biodel inks deal with Becton, Dickinson for injection system https://seekingalpha.com/news/1468381-biodel-inks-deal-with-becton-dickinson-for-injection-system?source=tweet\" data-url=\"https://seekingalpha.com/news/1468381-biodel-inks-deal-with-becton-dickinson-for-injection-system\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468221\" data-ts=\"1387284814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMTI\" target=\"_blank\">RMTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468221-brean-sees-fda-rejecting-rockwells-triferic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brean sees FDA rejecting Rockwell&#39;s Triferic</a></h4><ul>\n<li>Brean is out with a decisively negative note on Rockwell Medical (NASDAQ:<a href=\"https://seekingalpha.com/symbol/RMTI\" title=\"Rockwell Medical, Inc.\">RMTI</a>), calling Triferic \"far from terrific.\"</li>\n<li>Analyst Jonathan Aschoff doesn't mince words in initiating the shares at Sell: \"We believe the FDA will reject Triferic due to poor clinical trial design and questionable efficacy.\"</li>\n<li>\"CRUISE had a questionable design that we view as unlikely to result in approval,\" Aschoff says, elaborating. \"More than 80% of the patients in all CRUISE arms did not complete the 48-week treatment period, making the primary endpoint evaluation period highly variable.\"</li>\n<li><em>Price target is $4, representing downside of more than 70% from Monday's close. </em></li>\n<li>For more on the CRUISE trials, see <a href=\"https://seekingalpha.com/currents/search?query=ROCKWELL%20SFP\" target=\"_blank\">here</a>.  </li>\n<li>RMTI <font color=\"red\">-7%</font> premarket</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"1468221\" data-linked=\"Brean sees FDA rejecting Rockwell&#39;s Triferic\" data-tweet=\"$RMTI - Brean sees FDA rejecting Rockwell&#39;s Triferic https://seekingalpha.com/news/1468221-brean-sees-fda-rejecting-rockwells-triferic?source=tweet\" data-url=\"https://seekingalpha.com/news/1468221-brean-sees-fda-rejecting-rockwells-triferic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1468161\" data-ts=\"1387283934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1468161-frontier-communications-lands-at-and-ts-connecticut-wireline-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontier Communications lands AT&amp;T&#39;s Connecticut wireline business</a></h4><ul> <li>Frontier Communications (NYSE:<a href=\"https://seekingalpha.com/symbol/FTR\" title=\"Frontier Communications Corporation\">FTR</a>) buys AT&amp;T's (NYSE:<a href=\"https://seekingalpha.com/symbol/T\" title=\"AT&amp;T Inc.\">T</a>) wireline residential and business service that serves Connecticut for $2B in cash and related assets.</li> <li>The company expects the transaction to be accretive in the first year following the closing which is targeted for the second half of 2014 following regulatory approvals.</li> <li>FTR <font color=\"green\">+13.8%</font> premarket.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"1468161\" data-linked=\"Frontier Communications lands AT&amp;T&#39;s Connecticut wireline business\" data-tweet=\"$FTR $FTR $T - Frontier Communications lands AT&amp;T&#39;s Connecticut wireline business https://seekingalpha.com/news/1468161-frontier-communications-lands-at-and-ts-connecticut-wireline-business?source=tweet\" data-url=\"https://seekingalpha.com/news/1468161-frontier-communications-lands-at-and-ts-connecticut-wireline-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1467951\" data-ts=\"1387276544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1467951-world-markets-await-the-fed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">World markets await the Fed</a></h4><ul>   <li>Asian shares are mixed, while European equities and U.S. stock futures are flat-to-lower as investors await the outcome of a two-day FOMC meeting today and tomorrow.</li>    <li>The main question is whether the Fed will decide to start scaling back its bond-buying program. A budget deal in Congress and solid economic data lately suggest that the chances of the taper have gone up.</li>     <li>\"Although we have heavier odds pinned on the tapering being announced in January, we think the economic case has already been made for <a href=\"http://www.reuters.com/article/2013/12/17/us-markets-global-idUSBRE96S00E20131217\" target=\"_blank\">pulling the trigger</a>,\" Societe Generale analysts wrote in a note.</li>    <li>Japan <font color=\"green\">+0.8%</font>, Hong Kong <font color=\"red\">-0.2%</font>, China <font color=\"red\">-0.45%</font>, India <font color=\"red\">-0.2%</font>.</li>    <li>EU Stoxx 50 <font color=\"red\">-0.6%</font>, London <font color=\"red\">-0.5%</font>, Paris <font color=\"red\">-1%</font>, Frankfurt <font color=\"red\">-0.4%</font>, Milan <font color=\"red\">-0.5%</font>, Madrid <font color=\"red\">-0.4%</font>.</li>     <li>U.S. stock futures: Dow flat. S&amp;P <font color=\"red\">-0.1%</font>. Nasdaq <font color=\"red\">-0.1%</font>\n</li> </ul><div class=\"tiny-share-widget\" data-id=\"1467951\" data-linked=\"World markets await the Fed\" data-tweet=\"World markets await the Fed https://seekingalpha.com/news/1467951-world-markets-await-the-fed?source=tweet\" data-url=\"https://seekingalpha.com/news/1467951-world-markets-await-the-fed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":45,"message":null,"success":true,"today":{"start":1576818000,"end":1576904399,"str":"Friday, December 20, 2019"},"yesterday":{"start":1576731600,"end":1576817999}}